A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

CompletadoClinicalTrials.gov

ID: NCT01511913Tipo: OBSERVATIONALInicio: 3 de jun de 2012Fin estimado: 12 de dic de 2019

Traducción no disponible, mostrando original

Resumen

The purpose of this study is to examine the safety of Ipilimumab and patterns of use in the treatment of unresectable or metastatic melanoma in the post-approval setting

Descripción detallada

Time Perspective: this study does have a retrospective component involving a subset of patients

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Diagnosis of unresectable or metastatic melanoma
Age of 18 years or older at time of entry into the study
Patients who have initiated treatment for unresectable or metastatic melanoma at medical practice (e.g. community-based, office-based, hospital-based, academic setting)within 21 days before informed consent for this study OR in the case where treatment has not yet been initiated, documentation that the treatment strategy was determined before informed consent for this study, and treatment must be initiated within 28 days after informed consent
Ipilimumab-treated patients must be receiving treatment for the indication(s) approved in their country of residence or where they are receiving treatment

Criterios de exclusión

Current or pending participation in a clinical trial examining therapy for the treatment of any cancer (including unresectable or metastatic melanoma)
Current use of therapy to treat a primary cancer other than melanoma

Ubicaciones

Local Institution

CABA, Argentina

Local Institution

CABA, Argentina

Local Institution

CABA, Argentina

Local Institution

Córdoba, Argentina

Local Institution

Rosario- Santa Fe, Argentina

Local Institution

San Miguel de Tucumán, Argentina

Patrocinadores

PrincipalBristol-Myers Squibb

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Multi-National, Prospective, Observational Study in Pat... | EligiMed